Arcus Biosciences, Inc. Banner Image

Arcus Biosciences, Inc.

  • Ticker RCUS
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Arcus Biosciences, Inc. Logo Image
  • 201-500 Employees
  • Based in Hayward, California
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies acrossMore multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for first-line treatment of metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio.
Arcus Biosciences, Inc.

Most Recent Annual Report

Arcus Biosciences, Inc.
MOST RECENT 2021 Form 10K

Older/Archived Annual Reports